Back to today’s briefing

Story perspectives

Edenbridge Pharmaceuticals Faces FDA Backlash Over Misleading Claims

3/5/2025

49 7

Summary

Story summary

Edenbridge Pharmaceuticals faces backlash from the FDA for making false claims about its Hemady treatment for multiple myeloma, asserting it outperformed generics. The agency criticized the company's promotional materials for omitting vital risk information and highlighted a flawed study design that failed to validate their claims about patient adherence.

1 of 1

Story summary

Edenbridge Pharmaceuticals faces backlash from the FDA for making false claims about its Hemady treatment for multiple myeloma, asserting it outperformed generics. The agency criticized the company's promotional materials for omitting vital risk information and highlighted a flawed study design that failed to validate their claims about patient adherence.